

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Michael T. Migawa et al.** Confirmation No.: **2825**  
Serial No.: **10/592,919** Group Art Unit: **Not assigned**  
Filed: **9/15/2006** Examiner: **Not Assigned**  
Title: **COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE  
OF RNA BY RNASE H**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported throughout the application, as filed. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825(b), is the same as the amended paper Sequence Listing.

Respectfully submitted,

  
Clifford Ford  
Registration No. 52,903

Date: 7/31/2007

ISIS Pharmaceuticals, Inc.  
1896 Rutherford Rd.  
Carlsbad, CA 92008  
Telephone: (760) 931-9200  
Facsimile: (760) 603-3820